Initial screenings include Chest X-rays and CT scans, often revealing pleural thickening or pleural effusion (fluid buildup).
Malignant Pleural Mesothelioma (MPM) is a rare, aggressive cancer originating in the mesothelial cells of the pleura, the thin membrane surrounding the lungs. It is almost uniquely associated with asbestos exposure and is characterized by a long latency period, difficult diagnosis, and poor prognosis. Etiology and Pathogenesis
Exposure to erionite (a mineral), radiation therapy, and the BAP1 genetic mutation can increase risk.
Historically, the median survival rate for MPM has been 12 to 18 months. However, the landscape is shifting:
💡 While MPM remains a challenging malignancy, the shift from traditional chemotherapy toward personalized immunotherapy and lung-sparing surgery offers new hope for extending patient survival.
The standard first-line treatment for decades has been Cisplatin combined with Pemetrexed.
Initial screenings include Chest X-rays and CT scans, often revealing pleural thickening or pleural effusion (fluid buildup).
Malignant Pleural Mesothelioma (MPM) is a rare, aggressive cancer originating in the mesothelial cells of the pleura, the thin membrane surrounding the lungs. It is almost uniquely associated with asbestos exposure and is characterized by a long latency period, difficult diagnosis, and poor prognosis. Etiology and Pathogenesis malignant pleural mesothelioma
Exposure to erionite (a mineral), radiation therapy, and the BAP1 genetic mutation can increase risk. Initial screenings include Chest X-rays and CT scans,
Historically, the median survival rate for MPM has been 12 to 18 months. However, the landscape is shifting: Etiology and Pathogenesis Exposure to erionite (a mineral),
💡 While MPM remains a challenging malignancy, the shift from traditional chemotherapy toward personalized immunotherapy and lung-sparing surgery offers new hope for extending patient survival.
The standard first-line treatment for decades has been Cisplatin combined with Pemetrexed.